Day: August 15, 2022

On track to file New Drug Application for Renazorb, the first proprietary nanoparticle-based phosphate binder for Chronic Kidney Disease (CKD) patients, by end of 2023 Signed first global partnership for rights to Renazorb in China with Lee’s Pharmaceutical (HK) Ltd. to further advance global commercial strategy for product with a differentiated profile and ease of administration for CKD patients Expects to file regulatory submission to initiate a Phase 1 healthy volunteer study in 2H’22 with UNI-494, a novel proprietary drug targeting the SUR2 subunit of the mitochondrial KATP   channel activator LOS ALTOS, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the...

LONDON, Aug. 15, 2022 (GLOBE NEWSWIRE) — Ferroglobe PLC (NASDAQ: GSM) (“Ferroglobe”, the “Company”, or the “Parent”), a leading producer globally of silicon metal, silicon-based and manganese-based specialty alloys, today announced results for the second quarter 2022. FINANCIAL HIGHLIGHTSRecord Q2 2022 revenue of $840.8 million, up 17.6% over the prior quarter Record Q2 2022 Adjusted EBITDA of $303.2 million, up 25.7% over the prior quarter Adjusted EBITDA margin improvement of 234 basis points to 36.1% in Q2 2022, up from 33.7% the prior quarter Record net profit of $185.1 million (diluted earnings per share of $0.98), compared to net profit of $150.8 million (diluted earnings per share of $0.80) in Q1 2022 Net debt of $194 million at quarter end, significant decrease from $342 million at the end of Q1 Bolstered liquidity: total...

SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) — Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today reported its second quarter 2022 financial results and highlighted recent corporate progress. Recent Corporate ProgressMost recently in July, we completed a $5 million public offering. We continue to explore the possible effects of REVTx-99b for the treatment of allergies. Data from our preclinical and Phase 2 viral challenge clinical study (RVL-VRL01) suggest intranasal REVTx-200 may positively augment the immune response relative to vaccination alone and we anticipate preclinical data during the fourth quarter. We anticipate preclinical data for REVTx-300...

FREMONT, CA, Aug. 15, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results for the second quarter of 2022. Second Quarter 2022 Financial Results All comparisons are made on a year-over-year basis.Revenues. The Company generated $312,860 and $31,441 in revenues for the three months ended June 30, 2022 and 2021, respectively. The increase in revenues was mainly due to the revenue generated from the clinical development service agreement signed between BioKey and Rgene. Operating Expenses increased by $285,043, or 14%, to $2,351,353 for the three months ended June 30, 2022 from $2,066,310 for the three months ended June 30, 2021....

Revenue increased 34% to $8.5 million in Q2 2022 vs. $6.3 million in Q2 2021; YTD revenue increased 31% to $17.2 million vs. $13.2 million in 2021 Operating income increased 127% to $1.1 million in Q2 2022 vs. $0.5 million in Q2 2021; YTD operating income increased 166% to $2.5 million in Q2 2022 vs. $1.0 million in 2021 Strengthened balance sheet via redemption of Series C preferred stock at discount New asset management agreement covering Anchor Portfolio provides expanded revenue opportunities and extends term through 2035 Dwight Schar, recently retired CEO/Chairman of NVR, Inc. (NYSE: NVR), joining Comstock as significant shareholderRESTON, Va., Aug. 15, 2022 (GLOBE NEWSWIRE) — Comstock Holding Companies, Inc. (Nasdaq: CHCI) (“Comstock” or the “Company”) announced its financial results for the three and six months ended...

C$158.6 million in cash and short-term investments VANCOUVER, British Columbia, Aug. 15, 2022 (GLOBE NEWSWIRE) — Sabina Gold & Silver Corp. (“Sabina”) or (the “Company”) (SBB – TSX/ SGSVF – OTCQX) reports the interim financial results for the quarter ended June 30, 2022. “The second quarter was extremely busy for the Company,” said Bruce McLeod, the Company’s President & CEO. “We continued with our procurement efforts, our civil works and advancing the underground exploration ramp. In addition, we completed a very successful exploration program with results continuing to demonstrate opportunities for delivery of higher-grade material earlier in the mine life. We have also focused on building our team with a major recruiting and hiring campaign as we prepare for full construction next year. The quarter culminated...

Company continues to add high-margin titles to growing content library VANCOUVER, British Columbia, Aug. 15, 2022 (GLOBE NEWSWIRE) — Amcomri Entertainment Inc. (“Amcomri” or the “Company”) (NEO: AMEN) (OTC: AMNNF) (Frankfurt: 25YO), a global producer and distributor of independent movies, TV series and documentaries, announced today financial results for the three and six months ended June 30, 2022. All dollar amounts are in Canadian dollars unless otherwise stated. HighlightsGroup revenues for the six months ended June 30, 2022, were 6.0% ahead of the same comparable six-month period last year; EBITDA of $3,455,418 for the six months ended June 30, 2022, exceeded management budgets and fell just short of the same time period last year despite the impact of delays in production deliveries; Net income before translation adjustment...

On track for another record year in multiple business units NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES23% increase in revenue over the same period last year, reflecting higher patient volumes from the Company’s clinics, telehealth services, MCI Connect virtual healthcare services and the acquisitions of Khure Health (“Khure”) and the Polyclinic Group of Companies (“Polyclinic”) in 2021. Quarterly revenue of $13.8 million, on track for another record year in multiple business units. Polyclinic and Khure acquisitions performing well, with revenue growing over 500% for the rare disease data screening product anchored by Khure. Patient volumes up over 10% over the same period last year, excluding increases from acquisitions. Roll-out of the Company’s Data Insights as a Service offering, as the Company...